Antineoplastic Agents, Immunological Concept

subject area of

• A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies  Journal Articles
• A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis  Journal Articles
• Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?  Journal Articles
• Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.  Journal Articles
• Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma  Journal Articles
• Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world  Journal Articles
• Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial  Journal Articles
• Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma  Journal Articles
• Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review  Journal Articles
• Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer  Journal Articles
• Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis  Journal Articles
• Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221  Journal Articles
• Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events  Journal Articles
• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial  Journal Articles
• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study  Journal Articles
• Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma  Journal Articles
• Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12^*  Journal Articles
• Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites  Journal Articles
• Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)  Journal Articles
• Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors  Journal Articles
• Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review  Journal Articles
• Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer  Journal Articles
• Immunotherapy in the Elderly  Journal Articles
• Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses  Journal Articles
• Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients  Journal Articles
• Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab  Journal Articles
• Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial  Journal Articles
• Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use  Journal Articles
• Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013  Journal Articles
• Predictors of Immunotherapy-Induced Immune-Related Adverse Events  Journal Articles
• Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort  Journal Articles
• Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors  Journal Articles
• Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer  Journal Articles
• Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review  Journal Articles
• Targeted therapy for metastatic renal cell carcinoma  Journal Articles
• The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma  Journal Articles
• The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population  Journal Articles
• Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis  Journal Articles
• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials  Journal Articles